Dopamine receptors are the receptors through which dopamine exerts its biological effects, and they are being explored as therapeutic targets in ischemia reperfusion injury because selective activation or inhibition under I/R stress may influence neuroplasticity, blood-brain barrier integrity, oxidative stress inhibition, and anti-apoptotic signaling. They are pharmacologically targeted by agents including bromocriptine, PD168077, piribedil, salvianolic acid A, and tadalafil, indicating interest in both receptor agonism and broader modulatory strategies. The available literature highlights a 2026 review in International Journal of Biological Macromolecules (PMID:41819328) that specifically frames dopamine receptors as potential interventions for I/R-related damage. Overall, the key mechanistic themes are protection against oxidative injury, preservation of barrier function, and support of cell survival pathways during reperfusion stress.
Ischemia-reperfusion injury
- A review in International Journal of Biological Macromolecules argued that dopamine receptors are potential therapeutic targets for ischemia reperfusion injury, emphasizing selective activation or inhibition during I/R stress. (PMID:41819328)
- The review linked dopamine receptor modulation to neuroplasticity, blood-brain barrier integrity, oxidative stress inhibition, and anti-apoptotic effects. (PMID:41819328)
- Pharmacological interventions reported to target dopamine receptors include bromocriptine, PD168077, piribedil, salvianolic acid A, and tadalafil. (PMID:41819328)
- The literature suggests dopamine receptor-directed strategies may be relevant for limiting reperfusion-associated tissue damage. (PMID:41819328)